A second-generation CAR-M has been developed by integrating intracellular CD3ζ and toll-like receptor 4 intracellular toll/IL-1R (TIR) domains, with the capability to drive M1-like macrophage polarization, exhibiting superior anti-tumor functions relative to first-generation CAR-M [41]. The gene discussed is TLR4; the disease is neoplasm.